152 related articles for article (PubMed ID: 37803853)
61. Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study.
Li C; Cai X; Chen X; Liang Y; Xia Z; Wang H
Int J Hematol; 2019 Oct; 110(4):458-465. PubMed ID: 31321731
[TBL] [Abstract][Full Text] [Related]
62. [The Factors Related to Treatment Failure in Children with Acute Lymphoblastic Leukemia].
Gao W; Jiang MY; Gao L; Lu J; Xiao PF; He HL; Wang Y; Pan J; Ling J; Sun YN; Hu SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):661-668. PubMed ID: 34105454
[TBL] [Abstract][Full Text] [Related]
63. Prognostic significance of
Yuan Y; Li J; Xue TL; Hu HR; Lin W; Liu SG; Zhang RD; Zheng HY; Gao C
Leuk Lymphoma; 2022 Jul; 63(7):1624-1633. PubMed ID: 35129045
[No Abstract] [Full Text] [Related]
64. [The Factors Affecting Relapse in Pediatric B-cell Acute Lymphoblastic Leukemia Patients without Prognostic Fusion Genes Following Up for 10 years].
Jiang MY; Gao W; Gao J; Ling J; Pan J; Xiao PF; Lu J; He HL; Wang Y; Li J; Li JQ; Chai YH; Sun YN; Hu SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):12-17. PubMed ID: 35123597
[TBL] [Abstract][Full Text] [Related]
65. [Prognostic analysis of children with Philadelphia chromosome-like acute lymphoblastic leukemia common genes].
Hu WD; Li B; Su SF; Liu YF; Liu W; Zhang WL; Zuo WL; Yu RH
Zhonghua Er Ke Za Zhi; 2023 May; 61(5):446-452. PubMed ID: 37096265
[No Abstract] [Full Text] [Related]
66. Characteristics and prognosis of children with recurrent T-cell acute lymphoblastic leukemia: a long-term follow-up report in China.
Liu X; Zou Y; Zhang L; Zhang Y; Chen Y; Chen X; Guo Y; Yang W; Zhu X
Leuk Lymphoma; 2022 Dec; 63(14):3462-3474. PubMed ID: 36107030
[TBL] [Abstract][Full Text] [Related]
67. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
[TBL] [Abstract][Full Text] [Related]
68. [Effect of Chemotherapy Course Delay on the Relapse of Paediatric B-cell Acute Lymphoblastic Leukemia].
Cao L; Gao J; Gao W; Liu H; Lu J; Wang Y; He HL; Xiao PF; Li J; Li JQ; Hu SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1034-1039. PubMed ID: 35981359
[TBL] [Abstract][Full Text] [Related]
69. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
70. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
71. [Outcome of childhood T-cell acute lymphoblastic leukemia: a report of 99 cases].
Cai JY; Xue HL; Chen J; Shen SH; Pan C; Wang X; Zhou M; Tang YJ; Gao YJ; Wang JM; Tang JY
Zhonghua Er Ke Za Zhi; 2016 Jun; 54(6):456-60. PubMed ID: 27256235
[TBL] [Abstract][Full Text] [Related]
72. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
Yu CH; Jou ST; Su YH; Coustan-Smith E; Wu G; Cheng CN; Lu MY; Lin KH; Wu KH; Chen SH; Huang FL; Chang HH; Wang JL; Yen HJ; Li MJ; Chou SW; Ho WL; Liu YL; Chang CC; Lin ZS; Lin CY; Chen HY; Ni YL; Lin DT; Lin SW; Yang JJ; Ni YH; Pui CH; Yu SL; Yang YL
Cancer; 2023 Mar; 129(5):790-802. PubMed ID: 36537587
[TBL] [Abstract][Full Text] [Related]
73. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
[TBL] [Abstract][Full Text] [Related]
74. [Clinical Features and Prognosis of Acute Lymphoblastic Leukemia Children with P2RY8-CRLF2 Gene Rearrangement].
Zheng YZ; LE SH; Zheng H; Hua XL; Chen ZS; Zheng L; Chen C; Li M; Cai CX; Yang JH; Chen YQ; Gao QL; Chen YY; Li J; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):311-315. PubMed ID: 33812392
[TBL] [Abstract][Full Text] [Related]
75. [Multicenter clinical trial of acute lymphoblastic leukemia in elder children and adolescents].
Zhang N; Shen SH; Wang NL; Li H; Yang JW; Shao JP; Jiang H; Tang JY
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):717-723. PubMed ID: 30369180
[No Abstract] [Full Text] [Related]
76. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
77. Efficacy and toxicity of high-risk therapy of the Dutch Childhood Oncology Group in childhood acute lymphoblastic leukemia.
van Binsbergen AL; de Haas V; van der Velden VHJ; de Groot-Kruseman HA; Fiocco MF; Pieters R
Pediatr Blood Cancer; 2022 Feb; 69(2):e29387. PubMed ID: 34648216
[TBL] [Abstract][Full Text] [Related]
78. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
79. [Clinical Analysis of Pediatric Acute Myeloid Leukemia with CCLG-AML 2015 Regimen].
Wang P; Xiong H; Li JX; Wang Z; Yang L; Tao F; Chen Z; DU Y; Zhang AP; Luo LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):373-380. PubMed ID: 35395966
[TBL] [Abstract][Full Text] [Related]
80. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
